Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for…
AOP Health’s Rapiblyk® (landiolol) Now Accessible via Vizient® Contract AOP Health US, LLC announced today that Rapiblyk® (landiolol) is now more widely available across the United States through contract with Vizient®, the nation’s largest provider-driven healthcare performance improvement company. Hospitals and…
Magnus Medical Announces First Patient Enrolled at University of Massachusetts in Pivotal DoD-Funded Multisite Study of SAINT for Postpartum Depression Magnus Medical, Inc., a pioneering therapeutic neuromodulation company advancing precision medicine in brain health, today announced enrollment of the first…
Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month* Hims & Hers Health, Inc. the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers…
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026 Revvity, Inc. announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference…
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS) Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced topline results from the STARLIGHT™ 2 Phase 3 pivotal study for…
Biogen’s Litifilimab Earns FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus—First Targeted Therapy on the Horizon Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous…
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001 Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced that its investigational cell therapy, OpCT-001, has received…
Legend Biotech Showcases Latest Business Developments at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today provided an update on the Company’s recent commercial and clinical progress and outlined its…
BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of…
The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Gordian Bio Enters Research Partnership with Pfizer to Drive Obesity Target Discovery Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to…
